How to Select a Jordan AR: Due Diligence in a Fragmented Licence-Holder Market

1. Key takeaways

The licence-holder landscape for medical devices in Jordan is highly fragmented: the JFDA medical device database contains roughly 918 licensed applicants, the top ten licence holders together account for about 16%, and the largest holder carries 246 registrations, or roughly 2.66%. GRZAN’s conclusion is that this structure gives manufacturers strong negotiating leverage when selecting a partner, but it also means that selecting an AR by total licence volume is the wrong method. For a manufacturer entering the market, this distribution of registrations means that no single partner is indispensable and that the bargaining table is genuinely open.

• Second conclusion: the correct screening dimension is category fit, not licence volume. In a fragmented market, small and mid-sized agents are often willing to invest more in market promotion, clinical evaluation and local tenders in order to win exclusive distribution rights.
• Third conclusion: three dimensions are mandatory checks for any candidate — category fit, warehouse qualification (GSP and JFDA acceptance), and vigilance capability (adverse event reporting and execution of field safety corrective actions, FSCA).

2. Legal basis

The selection of an authorised representative and the market structure described above rest on the following instruments and data sources.

Clause numbers must be verified against the Arabic originals published in the Official Gazette of Jordan and issued by the JFDA; the figures of 918 applicants, 16%, 246 registrations and 2.66% are industry statistics based on the JFDA registration database (practical estimate).

3. Expert insights

Insight 1: fragmentation is the structural feature that distinguishes Jordan from other Middle East markets. In Saudi Arabia or the United Arab Emirates, a small number of large healthcare groups control the mainstream public hospitals and the government tender channels, and small and mid-sized Chinese brands have limited bargaining power. Jordan has no absolute monopolist holding more than 3% of registrations, so the negotiating space for manufacturers is significantly larger (practical estimate). In other words, it is the structure of the licence-holder base, rather than the size of the market, that creates the leverage.

Insight 2: category fit predicts success better than total licence volume. Manufacturers of dental and surgical instruments should give priority to warehouse holders that already have promotion coverage across private dental clinics and cosmetic surgery clinic networks. IVD manufacturers should instead look at whether the candidate holds cold chain warehousing capability and established relationships with laboratory customers. A partner that already sells into the relevant clinical settings brings an installed customer base, so a completed registration converts into revenue faster.

Insight 3: warehouse qualification is a hard constraint, not a soft indicator. The registration is bound to a physical warehouse, and the warehouse must meet good distribution practice (GSP) or the storage standards set by the JFDA, with temperature and humidity monitoring and a segregated area for nonconforming products. An AR whose warehouse has not passed JFDA acceptance cannot complete the registration. Since the registration cannot exist without an accepted warehouse, the warehouse check is effectively a check on whether the candidate can deliver a registration at all.

Insight 4: vigilance capability determines post-market risk. The AR bears the management duties for post-market surveillance, complaint handling and vigilance activities. An AR that lacks vigilance capability will let adverse events that could have been handled in time escalate into regulatory incidents.

Insight 5: the lowest quotation carries hidden costs. Selecting an AR purely on the lowest offer commonly means selecting an entity without the regulatory capability or the JFDA relationship needed to handle complex queries and objection procedures. The registration timeline then extends from 4 months to more than 12 months (practical estimate). The saving on the quotation is then dwarfed by the cost of a stalled registration and a delayed market entry.

4. Practical recommendations

• Build the candidate list by category fit. Search licence holders by product category in the JFDA registration database rather than ranking candidates by their total number of registrations.
• Verify the warehousing conditions on site. Three items are mandatory checks: whether the temperature and humidity monitoring records are continuous, whether the segregation area for nonconforming products is independent, and whether the warehouse has passed JFDA acceptance. The verification should be scheduled before any exclusivity is discussed.
• Test the vigilance response capability. During due diligence, present simulated scenarios and ask the candidate to describe its adverse event reporting procedure and its experience with executing field safety corrective actions.
• Make registration milestones a condition of the commercial terms. Write registration timeline commitments and deficiency response deadlines into the agreement, and tie them to the continuation of exclusivity or to fee payments. Deficiency response deadlines deserve the same precision as the timeline itself.

5. Verification checklist

• □ Search the JFDA registration database by product category and build the candidate AR list
• □ Assess the category fit of each candidate AR (end-user coverage network, customer structure)
• □ Verify on site that the warehouse has passed JFDA acceptance and meets GSP
• □ Verify the continuity of temperature and humidity monitoring records and the segregation area for nonconforming products
• □ Assess the vigilance reporting and FSCA execution capability of each candidate AR
• □ Write registration timeline commitments and deficiency response deadlines into the agreement
• □ Avoid using the lowest quotation as the only selection criterion
• □ Re-verify the cited clause numbers against the Arabic originals of the Official Gazette

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Jordanian market. Our team coordinates local importer arrangements, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com